Drug Profile
Research programme: gastric ulcer therapy - Medigreen
Alternative Names: MIC-31Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Medigreen Biotechnology Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes
Highest Development Phases
- No development reported Gastric ulcer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Gastric-ulcer in Taiwan (PO)
- 31 Jul 2007 MIC-31 is available for licensing as of 31 Jul 2007. http://www.medigreen.com
- 31 Dec 2005 Preclinical trials in Gastric ulcer in Taiwan (PO)